COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

The American Academy of Pediatrics has issued updated recommendations for RSV prevention in infants and high-risk young children.

Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.

A new report by Treatment Action Group (TAG) warns that a key ingredient in several vaccines of global health importance may face critical supply bottlenecks in the coming years unless governments, ...

EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...

Arexvy is GSK’s adjuvanted recombinant vaccine designed to prevent lower respiratory tract disease (LRTD) caused by RSV. Initially approved for adults aged 60 and older, as well as those aged 50-59 ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

The U.S. Food and Drug Administration said on Thursday it has expanded the use of GSK's Blujepa as an oral treatment for ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...